[Ip-health] Bridges Weekly: TPP-11 Negotiators Review Trade Deal Options Ahead of November Meet

Thiru Balasubramaniam thiru at keionline.org
Thu Sep 14 08:35:00 PDT 2017



Among the items that were reportedly major topics in Sydney included how to
treat TPP provisions in areas such as government procurement and
intellectual property rights for pharmaceutical products.

The latter topic had proven especially contentious in the final phase of
the original TPP negotiations, when the US was still a member, particularly
involving data exclusivity rules for biologic drugs. Washington had pushed
strongly for longer data exclusivity periods for such pharmaceuticals,
which are derived from a biological background. These drugs include
vaccines and gene therapies, among others. (See Bridges Weekly, 11 February
 and 8 October 2015

While some reports suggest that the current TPP’s provisions on data
exclusivity may be revised, that has not been formally confirmed at this
stage. Other substantive issues relating to intellectual property rights
and investment were reportedly raised and are expected to be the subject of
future discussions.

Other officials indicated that the Sydney talks had been fruitful, with
Kazuyoshi Umemoto, chief negotiator for the Japanese delegation, telling
Kyodo News that “common understanding between their various countries had

Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org

More information about the Ip-health mailing list